Li Minghan, Su Chang, Wang Qianru, Chen Yuetong, Jiang Di, Wang Weijia, Chen Shunjin, Li Xiangping, Fu Ming, Lu Juan
Department of Otolaryngology-Head and Neck Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China.
Discov Oncol. 2025 Jan 27;16(1):94. doi: 10.1007/s12672-025-01803-0.
The zinc finger protein 32 (ZNF32) has been associated with high expression in various cancers, underscoring its significant function in both cancer biology and immune response. To further elucidate the biological role of ZNF32 and identify potential immunotherapy targets in cancer, we conducted an in-depth analysis of ZNF32. We comprehensively investigated the expression of ZNF32 across tumors using diverse databases, including TCGA, CCLE, TIMER2.0, KM-Plotter, cBioPortal, ImmuCellAI. We investigated correlations between ZNF32 expression and various factors such as prognosis, immune infiltration, immunotherapy, DNA methylation, and biological functions. Furthermore, we performed in vitro research to validate the significance of ZNF32 in head and neck cancer (HNSC). Our study revealed that ZNF32 was high in various types of cancer, including ACC, BRCA, and others, indicating its important potential as a prognostic biomarker. Significant changes in CNA and DNA methylation were associated with high ZNF32 expression. ZNF32 was notably linked to various immune characteristics, including immune cell infiltration, MSI, TMB and immune checkpoint gene expression, indicating its potential in informing immunotherapy approaches. Interestingly, in FaDu and CAL27 cell lines, the group with elevated ZNF32 expression exhibited increased levels of immune checkpoint markers, such as CTLA-4 and PD-L1. Overexpression of ZNF32 significantly enhanced proliferation and migration in FaDu and CAL27 cell lines, as demonstrated through CCK-8 assays, colony formation, flow cytometry, Transwell migration, and Boyden invasion assays. Our in vitro experiments confirmed that ZNF32 promotes malignant behavior by driving HNSC cell proliferation and migration. These results imply that ZNF32 might be a promising target for tumor prognosis and immunotherapy. Our results highlight the important role of ZNF32 in tumorigenesis and provide novel perspectives for potential cancer treatment strategies.
锌指蛋白32(ZNF32)已被证实与多种癌症的高表达相关,这突出了其在癌症生物学和免疫反应中的重要作用。为了进一步阐明ZNF32的生物学作用并确定癌症潜在的免疫治疗靶点,我们对ZNF32进行了深入分析。我们使用包括TCGA、CCLE、TIMER2.0、KM-Plotter、cBioPortal、ImmuCellAI在内的多种数据库,全面研究了ZNF32在各类肿瘤中的表达情况。我们调查了ZNF32表达与多种因素之间的相关性,如预后、免疫浸润、免疫治疗、DNA甲基化和生物学功能。此外,我们进行了体外研究以验证ZNF32在头颈癌(HNSC)中的重要性。我们的研究表明,ZNF32在包括ACC、BRCA等多种类型的癌症中表达较高,表明其作为预后生物标志物具有重要潜力。拷贝数改变(CNA)和DNA甲基化的显著变化与ZNF32的高表达相关。ZNF32与多种免疫特征显著相关,包括免疫细胞浸润、微卫星不稳定性(MSI)、肿瘤突变负荷(TMB)和免疫检查点基因表达,表明其在指导免疫治疗方法方面的潜力。有趣的是,在FaDu和CAL27细胞系中,ZNF32表达升高的组显示出免疫检查点标志物(如CTLA-4和PD-L1)水平的增加。通过CCK-8测定、集落形成、流式细胞术、Transwell迁移和Boyden侵袭试验表明,ZNF32的过表达显著增强了FaDu和CAL27细胞系中的增殖和迁移能力。我们的体外实验证实,ZNF32通过驱动HNSC细胞增殖和迁移促进恶性行为。这些结果表明,ZNF32可能是肿瘤预后和免疫治疗的一个有前景的靶点。我们的结果突出了ZNF32在肿瘤发生中的重要作用,并为潜在的癌症治疗策略提供了新的视角。